慢性CaMKII激活驱动突变特异性肥厚型心肌病疾病进展
该研究在两种肌节性肥厚型心肌病小鼠模型(cTnT R92L与R92W)中评估早期干预钙稳态的效果。结果显示CaMKII抑制在R92W小鼠中恢复舒张功能并部分减轻心房重构,但在R92L小鼠中加重钙处理与功能异常;地尔硫䓬仅阻止R92W的舒张功能障碍进展。提示CaMKII激活在HCM进展中具有突变依赖性作用。
要点
- CaMKII抑制在R92W小鼠中恢复舒张功能并部分减轻心房重构。
- CaMKII抑制在R92L小鼠中加重心肌钙处理、重构和功能。
- 地尔硫䓬仅阻止R92W小鼠舒张功能障碍进展,两种基因型心脏重构均无改善。
核心结论
- 活化CaMKII在HCM进展中具有高度特异性、突变依赖性的作用,为特定队列HCM临床管理提供精确治疗靶点。
- 地尔硫䓬的突变特异性反应凸显了在分子水平理解突变依赖性进展以精确干预疾病进展的必要性。
研究设计与样本
- 使用两种肌节性HCM小鼠模型(心脏肌钙蛋白T R92L与R92W),具有不同的心肌细胞钙调节异常和疾病表现。
- 测试两种干预方式:通过AC3I肽抑制自激活的钙依赖性激酶CaMKII,以及使用L型钙通道拮抗剂地尔硫䓬。
- 采用二维超声心动图测定心脏功能和左心室重构,通过心房质量监测心房重构,测量肌浆网Ca2+ATP酶活性作为心肌细胞钙处理指标并与其受磷蛋白磷酸化状态调控耦合。
主要发现
- 在R92W动物6月龄时测得CaMKII磷酸化增加,表明该激酶在这些动物中自主活性增加。
- 抑制CaMKII导致R92W小鼠舒张功能恢复并部分减轻心房重构。
- R92W动物中功能改善伴随肌浆网Ca2+ATP酶活性增加,尽管CaMKII激活降低,可能表明心肌细胞钙处理改善。
- 在R92L动物中抑制CaMKII导致心肌细胞钙处理、重构和功能恶化。
- 地尔硫䓬仅阻止R92W动物舒张功能障碍进展,两种基因型心脏重构均无改善。
临床怎么用
- 对于特定突变队列的HCM患者,CaMKII抑制可能恢复舒张功能并部分减轻心房重构。
- 地尔硫䓬可能仅对特定突变型(如R92W相关)HCM患者阻止舒张功能障碍进展。
- 临床管理HCM需在分子水平理解突变依赖性进展以精确干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the genetic causes of hypertrophic cardiomyopathy (HCM) are widely recognized, considerable lag in the development of targeted therapeutics has limited interventions to symptom palliation. This is in part attributable to an incomplete understanding of how point mutations trigger pathogenic remodeling. As a further complication, similar mutations within sarcomeric genes can result in differential disease severity, highlighting the need to understand the mechanism of progression at the molecular level. One pathway commonly linked to HCM progression is calcium homeostasis dysregulation, though how specific mutations disrupt calcium homeostasis remains unclear. METHODS: To evaluate the effects of early intervention in calcium homeostasis, we used 2 mouse models of sarcomeric HCM (cardiac troponin T R92L and R92W) with differential myocellular calcium dysregulation and disease presentation. Two modes of intervention were tested: inhibition of the autoactivated calcium-dependent kinase (calmodulin kinase II [CaMKII]) via the AC3I peptide and diltiazem, an L-type calcium channel antagonist. Two-dimensional echocardiography was used to determine cardiac function and left ventricular remodeling, and atrial remodeling was monitored via atrial mass. Sarcoplasmic reticulum Ca2+ATPase activity was measured as an index of myocellular calcium handling and coupled to its regulation via the phosphorylation status of phospholamban. RESULTS: We measured an increase in phosphorylation of CaMKII in R92W animals by 6 months of age, indicating increased autonomous activity of the kinase in these animals. Inhibition of CaMKII led to recovery of diastolic function and partially blunted atrial remodeling in R92W mice. This improved function was coupled to increased sarcoplasmic reticulum Ca2+ATPase activity in the R92W animals despite reduction of CaMKII activation, likely indicating improvement in myocellular calcium handling. In contrast, inhibition of CaMKII in R92L animals led to worsened myocellular calcium handling, remodeling, and function. Diltiazem-HCl arrested diastolic dysfunction progression in R92W animals only, with no improvement in cardiac remodeling in either genotype. CONCLUSIONS: We propose a highly specific, mutation-dependent role of activated CaMKII in HCM progression and a precise therapeutic target for clinical management of HCM in selected cohorts. Moreover, the mutation-specific response elicited with diltiazem highlights the necessity to understand mutation-dependent progression at a molecular level to precisely intervene in disease progression.
引用
- Lehman SJ, Tal-Grinspan L, Lynn ML, et al. Chronic Calmodulin-Kinase II Activation Drives Disease Progression in Mutation-Specific Hypertrophic Cardiomyopathy. Circulation. 2019. PMID: 30586744. doi:10.1161/CIRCULATIONAHA.118.034549
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。